Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in two upcoming investor conferences:
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome platform company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today announced that management will host a conference call and live audio webcast on March 2, 2021 at 8:30 a.m. ET to discuss fourth quarter and full year 2020 results and provide a general business update.
While Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shareholders are probably generally happy, the stock hasn't had...
In this article we talked about Cathie Wood’s recent comments about money supply, inflation, interest rates, bitcoin and present Wood’s top 10 small-cap stock picks. Click to skip ahead our lengthy discussion and see Cathie Wood’s Top 5 Small-Cap Stock Picks. “The year has certainly started off in a wild way.” ARK Investment Management’s CEO, […]
New data from microbiome and metabolomic endpoints provide mechanistic support of Seres' positive Phase 3 results in recurrent C. difficile infection.
Differences in focus, size of holdings, and weightings add to difficulty in choosing the right fund. Why ARK Genomic Revolution and SPDR S&P Biotech ETFs stand out.
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the publication of data analyses from the Company’s Phase 1b trial of SER-287 in patients with active mild-to-moderate ulcerative colitis (UC), most of whom were failing current therapies. The study results demonstrated that SER-287 administration was associated with positive impacts on clinical remission, endoscopic improvement, modulation of the gastrointestinal microbiome, and a favorable tolerability profile.
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 11:40 a.m. ET.